๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Sumitomo Pharma Co., Ltd. (TYO:4506)
Japan flag Japan ยท Delayed Price ยท Currency is JPY
1,895.50
+2.00 (0.11%)
Nov 20, 2026, 9:04 AM JST

Sumitomo Pharma Earnings Call Transcripts

Fiscal Year 2027

  • Q2 revenue and core operating profit beat forecasts, prompting higher FY guidance on strong U.S. drug sales. A ยฅ15/share dividend is planned as restructuring advances, while development investment and U.S. payer dynamics remain key considerations.

  • Q1 FY 2026 saw strong revenue growth driven by U.S. sales of ORGOVYX and GEMTESA, offsetting declines from divestitures and expired agreements. Net profit rose on FX gains, while R&D and SG&A costs increased. Management remains cautious on full-year guidance, with dividend resumption under review.

Fiscal Year 2026

  • FY 2025 saw double-digit revenue and profit growth, driven by U.S. sales of ORGOVYX and GEMTESA, while Japan faced headwinds from loss of exclusivity and price revisions. FY 2026 guidance projects further revenue gains, increased R&D, and a focus on new product launches and financial stability.

  • Q3 FY2025 saw strong revenue and profit growth, driven by North American product sales and cost controls. Full-year guidance is unchanged due to expected Q4 seasonality, while oncology R&D and partnering timelines have shifted to maximize asset value.

  • Q2 FY2025 saw revenue and profit surge above forecasts, driven by strong North America sales, a JPY 49 billion gain from the China-Asia business transfer, and disciplined cost control. Full-year guidance was raised, with Orgovyx expected to surpass $1 billion in sales.

  • Q1 FY2025 saw strong revenue and profit growth, led by North America, with ORGOVYX and GEMTESA outperforming plans. Full-year guidance is unchanged due to uncertainties, but significant one-time gains are expected in H1. R&D and governance initiatives continue to advance.

Fiscal Year 2025